Jump to main content
Research Type: Reports
-
Modeling P-quad
Read More
-
Remdesivir Less Expensive for “Government Programs”? Not So Fast.
Read More
-
Blueprints for Indication-Specific Pricing
Read More
-
Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries
Read More
-
Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection
Read More
-
Overview of Original Subscription Model and Features of LA and WA Proposals
Read More
-
DPL Responds to HHS RFI for IPI Drug Pricing Model (Nov. 30, 2018)
Read More
-
DPL responds to HHS Blueprint (May 16, 2018)
Read More
-
Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold
Read More
-
Does the 6% in Medicare Part B Drug Reimbursement Affect Prescribing?
Read More